Using Inhibitors as a Therapy for Lung Cancer

Technology #d-0928

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Categories
Researchers
Weimin Gao
His current research focuses on molecular epidemiology, early detection of cancers, cancer chemoprevention, cancer therapy, and proteomics.
External Link (www.tiehh.ttu.edu)
Managed By
David Snow
Director Intellectual Property 806-834-4989
Patent Protection

Provisional Patent Application Filed

PCT Patent Application Filed
Publications
Chemotherapeutic Sensitization of Leptomycin B Resistant Lung Cancer Cells by Pretreatment with Doxorubicin
Open Access,
Files and Attachments
Presentation-_Seminar10032012.pdf [PDF]

Lung cancer is the leading cause of cancer deaths worldwide, in part because of chemo-resistance. Using a combination therapy with a novel CRM1 inhibitor has shown to prolong survival for lung cancer. Research has shown very low doses of the inhibitor administered with traditional chemotherapeutic agents reduce toxicity effects compared to other treatments, while extending survival. 

Market Applications:

Therapeutics

Features, Benefits, and Advantages:

The novel addition of CRM1 (chromosome maintenance region 1) inhibitors, to current treatment regimens of cisplatin and doxorubicin increase cytotoxicity in vitro. A very low, non-toxic dose was tested in the laboratory and showed astounding results in inhibiting lung cancer cell growth in vivo.

-  This combination has shown to be more efficacious in in vivo than traditional treatments for lung cancer.

-  The strength of response is surprising, given the small amount of inhibitor administered.

-  Therapy with the inhibitor may have significance in other types of cancer.

Development Stage:

Mice work has been completed, in preparation for clinical trial, and data is available upon request.